IRIS
LODOLA, Alessio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.758
AS - Asia 7.312
EU - Europa 6.209
SA - Sud America 1.094
AF - Africa 427
Continente sconosciuto - Info sul continente non disponibili 354
OC - Oceania 4
Totale 25.158
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.401
SG - Singapore 2.542
CN - Cina 1.951
IT - Italia 1.728
VN - Vietnam 1.177
BR - Brasile 826
IE - Irlanda 826
FI - Finlandia 822
SE - Svezia 692
DE - Germania 656
HK - Hong Kong 510
FR - Francia 294
ZA - Sudafrica 277
UA - Ucraina 244
BD - Bangladesh 238
GB - Regno Unito 205
NL - Olanda 205
TR - Turchia 205
CA - Canada 201
IN - India 190
RU - Federazione Russa 125
AT - Austria 93
AR - Argentina 91
CI - Costa d'Avorio 70
ID - Indonesia 67
BE - Belgio 65
MX - Messico 65
JP - Giappone 61
ES - Italia 50
PL - Polonia 48
KR - Corea 44
IQ - Iraq 43
VE - Venezuela 40
PK - Pakistan 39
TH - Thailandia 38
CZ - Repubblica Ceca 37
EC - Ecuador 37
PH - Filippine 36
CO - Colombia 32
JO - Giordania 27
LT - Lituania 23
SA - Arabia Saudita 21
MA - Marocco 20
CR - Costa Rica 17
PY - Paraguay 17
CL - Cile 16
TW - Taiwan 16
UZ - Uzbekistan 16
KE - Kenya 14
RO - Romania 14
JM - Giamaica 13
MY - Malesia 12
PE - Perù 12
BO - Bolivia 11
HU - Ungheria 11
HR - Croazia 10
TN - Tunisia 10
UY - Uruguay 10
AL - Albania 9
EG - Egitto 9
HN - Honduras 9
IL - Israele 9
TT - Trinidad e Tobago 9
PS - Palestinian Territory 8
ET - Etiopia 7
KZ - Kazakistan 7
MD - Moldavia 7
SV - El Salvador 7
AZ - Azerbaigian 6
DO - Repubblica Dominicana 6
DZ - Algeria 6
GT - Guatemala 6
KG - Kirghizistan 6
LB - Libano 6
NI - Nicaragua 6
RS - Serbia 6
SN - Senegal 6
CH - Svizzera 5
DK - Danimarca 5
NP - Nepal 5
OM - Oman 5
AE - Emirati Arabi Uniti 4
BG - Bulgaria 4
EU - Europa 4
IR - Iran 4
LV - Lettonia 4
NO - Norvegia 4
PA - Panama 4
BH - Bahrain 3
BS - Bahamas 3
BY - Bielorussia 3
CW - ???statistics.table.value.countryCode.CW??? 3
GP - Guadalupe 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
AO - Angola 2
AU - Australia 2
BB - Barbados 2
CY - Cipro 2
Totale 24.776
Salva come PNG Salva come JPEG
Città #
Singapore 1.263
Ashburn 1.226
San Jose 922
Dublin 820
Chandler 742
Santa Clara 647
Dallas 582
Parma 561
Hong Kong 479
Beijing 458
Ann Arbor 398
Ho Chi Minh City 369
Council Bluffs 304
Jacksonville 296
Boardman 292
Johannesburg 263
Hanoi 261
Dearborn 246
Munich 243
New York 217
Los Angeles 214
Nanjing 167
Shanghai 164
Izmir 161
Helsinki 153
Lauterbourg 147
Princeton 136
Hefei 129
Milan 125
Wilmington 112
Bremen 79
São Paulo 79
San Mateo 78
Bologna 75
Columbus 75
Toronto 72
Buffalo 71
Abidjan 70
Vienna 70
Shenyang 69
Washington 69
Haiphong 57
Brussels 54
Moscow 54
Tokyo 52
Kunming 49
London 49
Jinan 47
Montreal 46
Seattle 46
Chicago 44
Hebei 44
Rome 44
Da Nang 42
Frankfurt am Main 42
Nanchang 42
Turku 42
Jakarta 41
Modena 41
The Dalles 41
Düsseldorf 40
Guangzhou 40
Phoenix 40
Des Moines 37
Changsha 35
Seoul 35
Dong Ket 34
Brescia 33
Orem 33
Jiaxing 32
Warsaw 32
Rio de Janeiro 30
Woodbridge 30
Atlanta 29
Brooklyn 29
Tianjin 29
Nuremberg 28
Bangalore 27
Denver 27
Fremont 27
Naples 27
Stockholm 27
Houston 26
San Francisco 26
Mexico City 25
Ankara 23
Chennai 23
Pune 23
Amman 22
North Bergen 22
Bangkok 21
Hangzhou 21
Brno 20
Belo Horizonte 19
Dhaka 19
Lubbock 19
Manchester 19
Ottawa 19
Norwalk 18
Zhengzhou 18
Totale 14.865
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 370
A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence 308
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 297
Benzisothiazolinone Derivatives as Potent Allosteric Monoacylglycerol Lipase Inhibitors That Functionally Mimic Sulfenylation of Regulatory Cysteines 292
Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph–Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice 288
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 273
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 270
Targeting the Eph/ephrin system as anti-inflammatory strategy in IBD 265
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 264
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 248
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 234
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 233
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 233
A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors. 232
Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice 228
Amino acid derivatives as palmitoylethanolamide prodrugs: Synthesis, in vitro metabolism and in vivo plasma profile in rats 227
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties 227
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 226
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 224
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 223
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 223
N-Acylethanolamine Acid Amidase (NAAA): Structure, Function, and Inhibition 222
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 221
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 218
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 215
Discovery and development of Eph-ephrin antagonists endowed with antiangiogenic properties 213
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 209
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 202
Application of 3D-QSAR in the Rational Design of Receptor Ligands and Enzyme Inhibitors 201
Free-Energy Simulations Support a Lipophilic Binding Route for Melatonin Receptors 200
A catalytic mechanism for cysteine N-terminal nucleophile hydrolases, as revealed by free energy simulations 200
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability 199
Discovery and development of small molecules targeting Eph-ephrin system in glioblastoma: an academic history 198
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 193
Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor 189
NEW EPH ANTAGONISTS DISCRIMINATING BETWEEN EPH-AS AND EPH-BS CLASSES 188
Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs 188
N-Acylethanolamine Acid Amidase (NAAA): Mechanism of Palmitoylethanolamide Hydrolysis Revealed by Mechanistic Simulations 184
JAK3 Inhibitors: Covalent and Noncovalent Interactions of a Cyanamide Group Investigated by Multiscale Free-Energy Simulations 183
Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation 182
inibitori eph-ephrin biodisponibili oralmente 180
UniPR1331: small Eph/ephrin antagonist beneficial in intestinal inflammation by interfering with type-B signaling 179
Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids 179
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 178
Cyclohexylcarbamic Acid 3'- or 4'-Substituted Biphenyl-3-yl Esters of as Fatty Acid Amide Hydrolase Inhibitors: Synthesis, Quantitative Structure-Activity Relationships and Molecular Modelling Studies 169
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 168
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 168
Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity 166
Eph/ephrin targeting with a small molecule improves glucose tolerance in healthy and insulin-resistant mice 166
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 166
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 164
Analysis of adam12-mediated ephrin-a1 cleavage and its biological functions 164
QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation 164
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 163
Tetrahydroquinoline Ring as a Versatile Bioisostere of Tetralin for Melatonin Receptor Ligands 162
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 161
Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands. 160
N-(2-Oxo-3-oxetanyl)carbamic Acid Esters as N-Acylethanolamine Acid Amidase Inhibitors: Synthesis, Structure–Activity and Structure–Property Relationships. 160
PHARMACOLOGICAL CHARACTERIZATION OF NEW COMPOUNDS AIMED AT INHIBITING EPH-EPHRIN INTERACTION IN GLIOBLASTOMA 159
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 159
Evaluation of the anti-tumor activity of small molecules targeting eph/ephrins in apcmin j mice 159
Application of a SCC-DFTB QM/MM approach to the investigation of the catalytic mechanism of fatty acid amide hydrolase. 158
L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib 157
Spirotetrahydroisoquinoline-Based Histone Deacetylase Inhibitors as New Antifibrotic Agents: Biological Evaluation in Human Fibroblasts from Bronchoalveolar Lavages of Idiopathic Pulmonary Fibrosis Patients 156
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 156
APPLICATION OF COMPUTATIONAL METHODSTO THE DESIGN OF FATTY ACID AMIDE HYDROLASE(FAAH) INHIBITORS BASED ON A CARBAMICTEMPLATE STRUCTURE 155
Structure activity relationship of new EphA2 ligands 154
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 154
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 154
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 153
Applications and Advances of QM/MM methods in Computational Enzymology 152
Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations 152
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 151
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 151
Aromatic interactions and rotational strengths within protein environment: An electronic structural study on beta-lactamases from class A 149
Target-hopping: a useful approach to identify novel Eph receptor antagonists 149
The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells 147
Mechanistic Modeling of Monoglyceride Lipase Covalent Modification Elucidates the Role of Leaving Group Expulsion and Discriminates Inhibitors with High and Low Potency 146
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists 146
UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice 146
Different roles for the acyl chain and the amine leaving group in the substrate selectivity of N-Acylethanolamine acid amidase 146
Identification of bivalent ligands with melatonin receptor agonist and fatty acid amide hydrolase (FAAH) inhibitory activity that exhibit ocular hypotensive effect in the rabbit 145
Cholenic acid derivative UniPR1331 impairs tumor angiogenesis via blockade of VEGF/VEGFR2 in addition to Eph/ephrin 145
Free-energy studies reveal a possible mechanism for oxidation-dependent inhibition of MGL 143
Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors 143
Role of sphingolipid metabolism in osimertinib-resistance in EGFR-mutated NSCLC models 142
Synthesis, Enantiomeric Resolution, and Structure-Activity Relationship Study of a Series of 10,11-Dihydro-5H-Dibenzo[a,d]cycloheptene MT(2) Receptor Antagonists. 142
MT2 selective melatonin receptor antagonists: design and structure-activity relationships 142
Metadynamics Simulations Distinguish Short- and Long-Residence-Time Inhibitors of Cyclin-Dependent Kinase 8. 142
In silico drug discovery of melatonin receptor ligands with therapeutic potential 141
Predicting the reactivity of nitrile-carrying compounds with cysteine: a combined computational and experimental study. 141
Pushing the Boundaries of Vinylogous Reactivity: Catalytic Enantioselective Mukaiyama Aldol Reactions of Highly Unsaturated 2-Silyloxyindoles 141
Eph-ephrin antagonism in tumor angiogenesis and growth: UniPR1331 preclinical evidence. 141
Unbinding Kinetics of Muscarinic M3 Receptor Antagonists Explained by Metadynamics Simulations 140
A catalytically silent FAAH-1 variant drives anandamide transport in neurons 140
The rare bile acid isoallolithocholic acid (IALCA) is an EphA2 antagonist sparing FXR and TGR5 receptors 138
Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. 138
Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines 138
N-tert-butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe (BOC2) inhibits the angiogenic activity of heparin-binding growth factors. 138
Irreversible EGFR inhibitor compounds with antiproliferative activity 137
Totale 18.393
Salva come PNG Salva come JPEG
Categoria #
all - tutte 85.769
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 85.769
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022686 0 0 0 0 58 28 109 100 58 67 35 231
2022/20233.112 314 309 172 240 288 358 41 196 983 45 127 39
2023/20241.256 82 72 42 43 89 270 118 111 46 64 142 177
2024/20254.391 137 217 271 250 455 481 273 263 563 399 382 700
2025/20269.230 796 966 1.110 823 1.200 490 978 310 1.127 725 413 292
2026/20271.996 223 446 542 768 17 0 0 0 0 0 0 0
Totale 25.158